Table 1 Global patient characteristics and according to groups
Characteristics | Total n = 76 | Discontinuation group n = 5 | Maintenance group n = 71 | |||
|---|---|---|---|---|---|---|
Age at diagnosis — yr (mean ±SD) | 4.4 ±2.7 | 4.1 ±2.2 | 4.5±2.7 | |||
Female — no. (%) | 49 | (64.5) | 4 | (80.0) | 45 | (63.4) |
First manifestation — no. (%) | ||||||
Arthritis | 38 | (50.0) | 2 | (40.0) | 36 | (50.7) |
Uveitis | 31 | (40.8) | 2 | (40.0) | 29 | (40.8) |
Both | 7 | (9.2) | 1 | (20.0) | 6 | (8.5) |
Uveitis — no. (%) | ||||||
JIA-associated uveitis | 52 | (68.4) | 3 | (60.0) | 49 | (69.0) |
Idiopathic uveitis | 24 | (31.6) | 2 | (40.0) | 22 | (31.0) |
ANA positive — no./total no. (%)a | 70/74 | (94.6) | 5 | (100) | 65/69 | (94.2) |
Type of uveitis — no. (%) | ||||||
Anterior | 67 | (88.2) | 4 | (80.0) | 63 | (88.7) |
Panuveitis | 9 | (11.8) | 1 | (20.0) | 8 | (11.3) |
Age at surgery — yr (mean ±SD) | 9.2 ±3.3 | 8.3±4.2 | 9.2±3.2 | |||
Surgery — no. (%) | ||||||
Cataract | 32 | (42.1) | 4 | (80.0) | 28 | (39.4) |
Posterior capsule opacification | 12 | (15.8) | 1 | (20.0) | 11 | (15.5) |
Glaucoma | 23 | (30.3) | 0 | (0.0) | 23 | (32.4) |
Needling | 4 | (5.3) | 0 | (0.0) | 4 | (5.6) |
Material removal | 3 | (3.9) | 0 | (0.0) | 3 | (4.2) |
Retinal detachment | 2 | (2.6) | 0 | (0.0) | 2 | (2.8) |
Immunosuppressive therapies — no. (%) | ||||||
Methotrexate + Adalimumab | 42 | (55.3) | 2 | (40.0) | 40 | (56.3) |
Methotrexate | 13 | (17.1) | 0 | (0.0) | 13 | (18.3) |
Methotrexate + Infliximab | 7 | (9.2) | 1 | (20.0) | 6 | (8.5) |
Adalimumab | 4 | (5.3) | 1 | (20.0) | 3 | (4.2) |
Etanercept | 4 | (5.3) | 0 | (0.0) | 4 | (5.6) |
Infliximab | 2 | (2.6) | 0 | (0.0) | 2 | (2.8) |
Abatacept | 1 | (1.3) | 1 | (20.0) | 0 | (0.0) |
Mycophénolic acid | 1 | (1.3) | 0 | (0.0) | 1 | (1.4) |
Azathioprine + Adalimumab | 1 | (1.3) | 0 | (0.0) | 1 | (1.4) |
Methotrexate + Abatacept | 1 | (1.3) | 0 | (0.0) | 1 | (1.4) |
Corticoid eye drops — no./total no. (%)a | 46/72 | (63.9) | 3/5 | (60.0) | 43/67 | (64.2) |
Oral corticoid — no. (%) | 31 | (40.8) | 2 | (40.0) | 29 | (40.8) |
Ophthalmic remission — no./total no. (%)a | 65/70 | (92.9) | 5/5 | (100) | 60/65 | (92.3) |
Preoperative adjustement— no./total no. (%)a | ||||||
Corticosteroids pulse | 21/74 | (28.4) | 2/5 | (40.0) | 19/69 | (27.5) |
Increase oral corticosteroids | 21/73 | (28.8) | 3/5 | (60.0) | 18/68 | (26.5) |
Peroperative adjustement — no./total no. (%)a | ||||||
Corticosteroids pulse | 29/69 | (42.0) | 2/5 | (40.0) | 27/64 | (42.2) |
Subconjunctival injection of corticosteroids | 39/62 | (62.9) | 4/5 | (80.0) | 35/57 | (61.4) |
Intracamerular corticosteroids | 11/61 | (18.0) | 0/5 | (0.0) | 11/56 | (19.6) |
Intracamerular antibiotics | 27/60 | (45.0) | 3/5 | (60.0) | 24/55 | (43.6) |
Antibiotics eyedrops | 51/60 | (85.0) | 2/5 | (40.0) | 49/55 | (89.1) |
Local antineoplastic drugs | 16/65 | (24.6) | 0/5 | (0.0) | 16/60 | (26.7) |
Postoperative adjustement — no./total no. (%)a | ||||||
Corticosteroids pulse | 18/72 | (25.0) | 2/5 | (40.0) | 16/67 | (23.9) |
Increase oral corticosteroids | 60/74 | (81.1) | 5/5 | (100) | 55/69 | (79.7) |
Corticosteroids eyedrops | 61/62 | (98.4) | 4/5 | (80.0) | 57/57 | (100) |
Antibiotics eyedrops | 59/59 | (100) | 5/5 | (100) | 54/54 | (100) |